Vivus reports weak sales of diet pill Qsymia

Wed May 8, 2013 7:50am EDT

May 8 (Reuters) - Vivus Inc reported weaker-than-expected quarterly sales of its diet drug Qsymia amid difficulties over reimbursement for obesity treatments and a restricted sales channel.

Net product revenue, reflecting sales of Qsymia, rose to $4.1 million in the first quarter from $2 million in the preceding quarter. The drug was launched late last year.

The company's net loss widened to $53.6 million, or 53 cents per share, from $18.8 million, or 20 cents per share, a year earlier.

Analysts had expected a loss of 51 cents per share on revenue of $5.2 million, according to Thomson Reuters I/B/E/S.

Qsymia was the first weight-loss pill to be launched in the United States in 13 years.

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article